Trial Profile

A phase 1 study of CR-001 in solid tumors.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CR-001-Crescent Biopharma (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

10 Apr 2025 New trial record
03 Apr 2025 According to Crescent Biopharma Media Release, company remains on track to submit an Investigational New Drug (IND) application for its lead program, CR-001, a tetravalent PD-1 x VEGF bispecific antibody, in the fourth quarter of 2025, with initial clinical data from a Phase 1 trial in patients with solid tumors expected in the second half of 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com